Tau protein phosphatases in Alzheimer's disease: The leading role of PP2A

Ageing Research Reviews

Volumn 12, Issue 1, 2013, Pages 39-49

  Martin, Ludovic ^a,b,c,d   Latypova, Xenia ^c   Wilson, Cornelia M ^a,b   Magnaudeix, Amandine ^a   Perrin, Marie Laure ^a   Terro, Faraj ^a,b  

^a UNIVERSITY OF LIMOGES   (France)

^b Hopital de la Mere et de l'Enfant   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d INSERM   (France)

Author keywords

Alzheimer's disease; Tau phosphatase inhibitors; Tau phosphorylation

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CALCINEURIN; CALYCULIN A; CANTHARIDIN; CYCLOSPORIN A; FOSTRIECIN; FUMONISIN B1; GLYCOGEN SYNTHASE KINASE 3BETA; MICROCYSTIN LR; NODULARIN; OKADAIC ACID; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE 5; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN KINASE B; TACROLIMUS; TAU KINASE; TAU PHOSPHATASE; TAU PHOSPHATASE INHIBITOR; TAU PROTEIN; TAUTOMYCETIN; TAUTOMYCIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; BRAIN DISEASE; DEGENERATIVE DISEASE; DEPHOSPHORYLATION; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; ANIMALS; ENZYME INHIBITORS; HUMANS; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN KINASES; PROTEIN PHOSPHATASE 2; TAU PROTEINS;

EID: 84867339738     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2012.06.008     Document Type: Review

References (214)

1. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und phychish-Gerichtliche Medizin, (Berlin) 1907, 64:146-148.
2. Andrabi S., Gjoerup O.V., Kean J.A., Roberts T.M., Schaffhausen B. Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:19011-19016.
3. Arnaud L., Chen S., Liu F., Li B., Khatoon S., Grundke-Iqbal I., Iqbal K. Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET. FEBS Letters 2011, 585:2653-2659.
4. Arnold H.K., Sears R.C. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer and Metastasis Reviews 2008, 27:147-158.
5. Atzori C., Ghetti B., Piva R., Srinivasan A.N., Zolo P., Delisle M.B., Mirra S.S., Migheli A. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. Journal of Neuropathology and Experimental Neurology 2001, 60:1190-1197.
6. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathologica 2002, 103:26-35.
7. Bennecib M., Gong C.X., Grundke-Iqbal I., Iqbal K. Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Letters 2000, 485:87-93.
8. Bertoli C., Copetti T., Lam E.W., Demarchi F., Schneider C. Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. Oncogene 2009, 28:721-733.
9. Biernat J., Gustke N., Drewes G., Mandelkow E.M., Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993, 11:153-163.
10. Blomqvist M.E., Reynolds C., Katzov H., Feuk L., Andreasen N., Bogdanovic N., Blennow K., Brookes A.J., Prince J.A. Towards compendia of negative genetic association studies: an example for Alzheimer disease. Human Genetics 2006, 119:29-37.
11. Brunden K.R., Trojanowski J.Q., Lee V.M. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nature Reviews Drug Discovery 2009, 8:783-793.
12. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:4240-4245.
13. Chen L., Liu L., Yin J., Luo Y., Huang S. Hydrogen peroxide-induced neuronal apoptosis is associated with inhibition of protein phosphatase 2A and 5, leading to activation of MAPK pathway. International Journal of Biochemistry and Cell Biology 2009, 41:1284-1295.
14. Chen L.M., Xiong Y.S., Kong F.L., Qu M., Wang Q., Chen X.Q., Wang J.Z., Zhu L.Q. Neuroglobin attenuates Alzheimer-like tau hyperphosphorylation by activating Akt signaling. Journal of Neurochemistry 2012, 120:157-164.
15. Chen M.X., Cohen P.T. Activation of protein phosphatase 5 by limited proteolysis or the binding of polyunsaturated fatty acids to the TPR domain. FEBS Letters 1997, 400:136-140.
16. Chen S., Li B., Grundke-Iqbal I., Iqbal K. I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. Journal of Biological Chemistry 2008, 283:10513-10521.
17. Chiang C.W., Kanies C., Kim K.W., Fang W.B., Parkhurst C., Xie M., Henry T., Yang E. Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Molecular and Cellular Biology 2003, 23:6350-6362.
18. Chin J.Y., Knowles R.B., Schneider A., Drewes G., Mandelkow E.M., Hyman B.T. Microtubule-affinity regulating kinase MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study. Journal of Neuropathology and Experimental Neurology 2000, 59:966-971.
19. Chinkers M. Protein phosphatase 5 in signal transduction. Trends in Endocrinology & Metabolism 2001, 12:28-32.
20. Cho U.S., Xu W. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 2007, 445:53-57.
21. Chohan M.O., Khatoon S., Iqbal I.G., Iqbal K. Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine. FEBS Letters 2006, 580:3973-3979.
22. Chung S.H. Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. BMB Report 2009, 42:467-474.
23. Cliff M.J., Williams M.A., Brooke-Smith J., Barford D., Ladbury J.E. Molecular recognition via coupled folding and binding in a TPR domain. Journal of Molecular Biology 2005, 346:717-732.
24. Cook C.N., Hejna M.J., Magnuson D.J., Lee J.M. Expression of calcipressin 1, an inhibitor of the phosphatase calcineurin, is altered with aging and Alzheimer's disease. Journal of Alzheimer's Disease 2005, 8:63-73.
25. Costa A.P., Tramontina A.C., Biasibetti R., Batassini C., Lopes M.W., Wartchow K.M., Bernardi C., Tortorelli L.S., Leal R.B., Goncalves C.A. Neuroglial alterations in rats submitted to the okadaic acid-induced model of dementia. Behavioural Brain Research 2012, 226:420-427.
26. da Cruz e Silva E.F., da Cruz e Silva O.A., Zaia C.T. Greengard P Inhibition of protein phosphatase 1 stimulates secretion of Alzheimer amyloid precursor protein. Molecular Medicine 1995, 1:535-541.
27. Dagda R.K., Merrill R.A., Cribbs J.T., Chen Y., Hell J.W., Usachev Y.M., Strack S. The spinocerebellar ataxia 12 gene product and protein phosphatase 2A regulatory subunit Bbeta2 antagonizes neuronal survival by promoting mitochondrial fission. Journal of Biological Chemistry 2008, 283:36241-36248.
28. Dagda R.K., Zaucha J.A., Wadzinski B.E., Strack S. A developmentally regulated, neuron-specific splice variant of the variable subunit Bbeta targets protein phosphatase 2A to mitochondria and modulates apoptosis. Journal of Biological Chemistry 2003, 278:24976-24985.
29. De Baere I., Derua R., Janssens V., Van Hoof C., Waelkens E., Merlevede W., Goris J. Purification of porcine brain protein phosphatase 2A leucine carboxyl methyltransferase and cloning of the human homologue. Biochemistry 1999, 38:16539-16547.
30. Derkinderen P., Scales T.M., Hanger D.P., Leung K.Y., Byers H.L., Ward M.A., Lenz C., Price C., Bird I.N., Perera T., Kellie S., Williamson R., Noble W., Van Etten R.A., Leroy K., Brion J.P., Reynolds C.H., Anderton B.H. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. Journal of Neuroscience 2005, 25:6584-6593.
31. Deters N., Ittner L.M., Gotz J. Substrate-specific reduction of PP2A activity exaggerates tau pathology. Biochemical and Biophysical Research Communications 2009, 379:400-405.
32. Dickey C.A., Dunmore J., Lu B., Wang J.W., Lee W.C., Kamal A., Burrows F., Eckman C., Hutton M., Petrucelli L. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB Journal 2006, 20:753-755.
33. Dickey C.A., Kamal A., Lundgren K., Klosak N., Bailey R.M., Dunmore J., Ash P., Shoraka S., Zlatkovic J., Eckman C.B., Patterson C., Dickson D.W., Nahman N.S., Hutton M., Burrows F., Petrucelli L. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. Journal of Clinical Investigation 2007, 117:648-658.
34. Edelson J.R., Brautigan D.L. The Discodermia calyx Toxin Calyculin A Enhances Cyclin D1 Phosphorylation and Degradation, and Arrests Cell Cycle Progression in Human Breast Cancer Cells. Toxins (Basel) 2012, 3:105-119.
35. Ermak G., Harris C.D., Battocchio D., Davies K.J. RCAN1 (DSCR1 or Adapt78) stimulates expression of GSK-3beta. FASEB Journal 2006, 273:2100-2109.
36. Ferrer I., Barrachina M., Puig B. Anti-tau phospho-specific Ser262 antibody recognizes a variety of abnormal hyper-phosphorylated tau deposits in tauopathies including Pick bodies and argyrophilic grains. Acta Neuropathologica 2002, 104:658-664.
37. Ferrer I., Blanco R., Carmona M., Ribera R., Goutan E., Puig B., Rey M.J., Cardozo A., Vinals F., Ribalta T. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathology 2001, 11:144-158.
38. Fruman D.A., Bierer B.E., Benes J.E., Burakoff S.J., Austen K.F., Katz H.R. The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. Journal of Immunology 1995, 154:1846-1851.
39. Fruman D.A., Klee C.B., Bierer B.E., Burakoff S.J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:3686-3690.
40. Fukuda H., Shima H., Vesonder R.F., Tokuda H., Nishino H., Katoh S., Tamura S., Sugimura T., Nagao M. Inhibition of protein serine/threonine phosphatases by fumonisin B1, a mycotoxin. Biochemical and Biophysical Research Communications 1996, 220:160-165.
41. Ghoshal N., Smiley J.F., DeMaggio A.J., Hoekstra M.F., Cochran E.J., Binder L.I., Kuret J. A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease. American Journal of Pathology 1999, 155:1163-1172.
42. Gong C.X., Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Current Medicinal Chemistry 2008, 15:2321-2328.
43. Gong C.X., Liu F., Wu G., Rossie S., Wegiel J., Li L., Grundke-Iqbal I., Iqbal K. Dephosphorylation of microtubule-associated protein tau by protein phosphatase 5. Journal of Neurochemistry 2004, 88:298-310.
44. Gong C.X., Shaikh S., Wang J.Z., Zaidi T., Grundke-Iqbal I., Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. Journal of Neurochemistry 1995, 65:732-738.
45. Gong C.X., Singh T.J., Grundke-Iqbal I., Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. Journal of Neurochemistry 1993, 61:921-927.
46. Greenwood J.A., Scott C.W., Spreen R.C., Caputo C.B., Johnson G.V. Casein kinase II preferentially phosphorylates human tau isoforms containing an amino-terminal insert, Identification of threonine 39 as the primary phosphate acceptor. Journal of Biological Chemistry 1994, 269:4373-4380.
47. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'Connor R., O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. Journal of Neurochemistry 2005, 93:105-117.
48. Hajduch E., Litherland G.J., Hundal H.S. Protein kinase B (PKB/Akt)-a key regulator of glucose transport?. FEBS Letters 2001, 492:199-203.
49. Hamilton G., Samedi F., Knight J., Archer N., Foy C., Walter S., Turic D., Jehu L., Moore P., Hollingworth P., O'Donovan M.C., Williams J., Owen M.J., Lovestone S., Powell J.F. Polymorphisms in the phosphate and tensin homolog gene are not associated with late-onset Alzheimer's disease. Neuroscience Letters 2006, 401:77-80.
50. Hanger D.P., Anderton B.H., Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends in Molecular Medicine 2009, 15:112-119.
51. Hanger D.P., Byers H.L., Wray S., Leung K.Y., Saxton M.J., Seereeram A., Reynolds C.H., Ward M.A., Anderton B.H. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. Journal of Biological Chemistry 2007, 282:23645-23654.
52. Hastie C.J., Cohen P.T. Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters. FEBS Letters 1998, 431:357-361.
53. Heimfarth L., Loureiro S.O., Reis K.P., de Lima B.O., Zamboni F., Lacerda S., Soska A.K., Wild L., da Rocha J.B., Pessoa-Pureur R. Diphenyl ditelluride induces hypophosphorylation of intermediate filaments through modulation of DARPP-32-dependent pathways in cerebral cortex of young rats. Archives of Toxicology 2012, 86:217-230.
54. Hemmings H.C., Greengard P., Tung H.Y., Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 1984, 310:503-505.
55. Hensley K., Floyd R.A., Zheng N.Y., Nael R., Robinson K.A., Nguyen X., Pye Q.N., Stewart C.A., Geddes J., Markesbery W.R., Patel E., Johnson G.V., Bing G. p38 kinase is activated in the Alzheimer's disease brain. Journal of Neurochemistry 1999, 72:2053-2058.
56. Hernandez F., Gomez de Barreda E., Fuster-Matanzo A., Lucas J.J. Avila J (GSK3: a possible link between beta amyloid peptide and tau protein. Experimental Neurology 2010, 223:322-325.
57. Hiraga A., Tamura S. Protein phosphatase 2A is associated in an inactive state with microtubules through 2A1-specific interaction with tubulin. Biochemical Journal 2000, 346(Pt 2):433-439.
58. Ho G.J., Drego R., Hakimian E., Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Current Drug Targets - Inflammation & Allergy 2005, 4:247-256.
59. Ho Y.S., Yang X., Lau J.C., Hung C.H., Wuwongse S., Zhang Q., Wang J., Baum L., So K.F., Chang R.C. Endoplasmic reticulum stress induces tau pathology and forms a vicious cycle: implication in Alzheimer's disease pathogenesis. Journal of Alzheimer's Disease 2012.
60. Honkanen R.E. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Letters 1993, 330:283-286.
61. Honkanen R.E., Dukelow M., Zwiller J., Moore R.E., Khatra B.S., Boynton A.L. Cyanobacterial nodularin is a potent inhibitor of type 1 and type 2A protein phosphatases. Molecular Pharmacology 1991, 40:577-583.
62. Honkanen R.E., Golden T. Regulators of serine/threonine protein phosphatases at the dawn of a clinical era?. Current Medicinal Chemistry 2002, 9:2055-2075.
63. Honkanen R.E., Zwiller J., Moore R.E., Daily S.L., Khatra B.S., Dukelow M., Boynton A.L. Characterization of microcystin-LR, a potent inhibitor of type 1 and type 2A protein phosphatases. Journal of Biological Chemistry 1990, 265:19401-19404.
64. Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer's disease. Journal of Neurochemistry 2008, 104:1433-1439.
65. Iqbal K., Liu F., Gong C.X. Alonso Adel C, Grundke-Iqbal I Mechanisms of tau-induced neurodegeneration. Acta Neuropathologica 2009, 118:53-69.
66. Isagawa T., Mukai H., Oishi K., Taniguchi T., Hasegawa H., Kawamata T., Tanaka C., Ono Y. Dual effects of PKNalpha and protein kinase C on phosphorylation of tau protein by glycogen synthase kinase-3beta. Biochemical and Biophysical Research Communications 2000, 273:209-212.
67. Ishihara H., Martin B.L., Brautigan D.L., Karaki H., Ozaki H., Kato Y., Fusetani N., Watabe S., Hashimoto K., Uemura D., et al. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochemical and Biophysical Research Communications 1989, 159:871-877.
68. Janssens V., Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochemical Journal 2001, 353:417-439.
69. Janssens V., Goris J., Van Hoof C. PP2A: the expected tumor suppressor. Current Opinion in Genetics and Development 2005, 15:34-41.
70. Janssens V., Longin S., Goris J. PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends in Biochemical Sciences 2008, 33:113-121.
71. Jicha G.A., Weaver C., Lane E., Vianna C., Kress Y., Rockwood J., Davies P. cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. Journal of Neuroscience 1999, 19:7486-7494.
72. Jones N.C., Nguyen T., Corcoran N.M., Velakoulis D., Chen T., Grundy R., O'Brien T.J., Hovens C.M. Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models. Neurobiology of Disease 2012.
73. Jones T.A., Barker H.M., da Cruz e Silva E.F., Mayer-Jaekel R.E., Hemmings B.A., Spurr N.K., Sheer D. Cohen PT (Localization of the genes encoding the catalytic subunits of protein phosphatase 2A to human chromosome bands 5q23→q31 and 8p12→p11.2, respectively. Cytogenetics and Cell Genetics 1993, 63:35-41.
74. Kawamata T., Taniguchi T., Mukai H., Kitagawa M., Hashimoto T., Maeda K., Ono Y., Tanaka C. A protein kinase, PKN, accumulates in Alzheimer neurofibrillary tangles and associated endoplasmic reticulum-derived vesicles and phosphorylates tau protein. Journal of Neuroscience 1998, 18:7402-7410.
75. Kerr F., Rickle A., Nayeem N., Brandner S., Cowburn R.F., Lovestone S. PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3. FEBS Letters 2006, 580:3121-3128.
76. Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 1963, 197:192-193.
77. Kimura R., Kamino K., Yamamoto M., Nuripa A., Kida T., Kazui H., Hashimoto R., Tanaka T., Kudo T., Yamagata H., Tabara Y., Miki T., Akatsu H., Kosaka K., Funakoshi E., Nishitomi K., Sakaguchi G., Kato A., Hattori H., Uema T., Takeda M. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Human Molecular Genetics 2007, 16:15-23.
78. Kovacech B., Kontsekova E., Zilka N., Novak P., Skrabana R., Filipcik P., Iqbal K., Novak M. A novel monoclonal antibody DC63 reveals that inhibitor 1 of protein phosphatase 2A is preferentially nuclearly localised in human brain. FEBS Letters 2007, 581:617-622.
79. Kuret J., Johnson G.S., Cha D., Christenson E.R., DeMaggio A.J., Hoekstra M.F. Casein kinase 1 is tightly associated with paired-helical filaments isolated from Alzheimer's disease brain. Journal of Neurochemistry 1997, 69:2506-2515.
80. Kuszczyk M., Gordon-Krajcer W., Lazarewicz J.W. Homocysteine-induced acute excitotoxicity in cerebellar granule cells in vitro is accompanied by PP2A-mediated dephosphorylation of tau. Neurochemistry International 2009, 55:174-180.
81. Layfield R., Fergusson J., Aitken A., Lowe J., Landon M., Mayer R.J. Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neuroscience Letters 1996, 209:57-60.
82. Lebouvier T., Scales T.M., Hanger D.P., Geahlen R.L., Lardeux B., Reynolds C.H., Anderton B.H., Derkinderen P. The microtubule-associated protein tau is phosphorylated by Syk. Biochimica et Biophysica Acta 2008, 1783:188-192.
83. Lebouvier T., Scales T.M., Williamson R., Noble W., Duyckaerts C., Hanger D.P., Reynolds C.H., Anderton B.H., Derkinderen P. The microtubule-associated protein tau is also phosphorylated on tyrosine. Journal of Alzheimer's Disease 2009.
84. Lee G., Thangavel R., Sharma V.M., Litersky J.M., Bhaskar K., Fang S.M., Do L.H., Andreadis A., Van Hoesen G., Ksiezak-Reding H. Phosphorylation of tau by fyn: implications for Alzheimer's disease. Journal of Neuroscience 2004, 24:2304-2312.
85. Lee V.M., Brunden K.R., Hutton M., Trojanowski J.Q. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harbor Perspectives in Medicine 2012, 1:a006437.
86. Leulliot N., Quevillon-Cheruel S., Sorel I., de La Sierra-Gallay I.L., Collinet B., Graille M., Blondeau K., Bettache N., Poupon A., Janin J., van Tilbeurgh H. Structure of protein phosphatase methyltransferase 1 (PPM1), a leucine carboxyl methyltransferase involved in the regulation of protein phosphatase 2A activity. Journal of Biological Chemistry 2004, 279:8351-8358.
87. Li D., Qu Y., Mao M., Zhang X., Li J., Ferriero D., Mu D. Involvement of the PTEN-AKT-FOXO3a pathway in neuronal apoptosis in developing rat brain after hypoxia-ischemia. Journal of Cerebral Blood Flow and Metabolism 2009.
88. Li L., Sengupta A., Haque N., Grundke-Iqbal I., Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Letters 2004, 566:261-269.
89. Li M., Damuni Z. I1PP2A and I2PP2A, Two potent protein phosphatase 2A-specific inhibitor proteins. Methods in Molecular Biology 1998, 93:59-66.
90. Li M., Guo H., Damuni Z. Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry 1995, 34:1988-1996.
91. Li M., Makkinje A., Damuni Z. Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A. Biochemistry 1996, 35:6998-7002.
92. Li X., Lu F., Tian Q., Yang Y., Wang Q., Wang J.Z. Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture. Journal of Neural Transmission 2006, 113:93-102.
93. Li X., Yost H.J., Virshup D.M., Seeling J.M. Protein phosphatase 2A and its B56 regulatory subunit inhibit Wnt signaling in Xenopus. EMBO Journal 2001, 20:4122-4131.
94. Li X.H., Lv B.L., Xie J.Z., Liu J., Zhou X.W., Wang J.Z. AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiology of Aging 2011.
95. Liang Z., Liu F., Iqbal K., Grundke-Iqbal I., Wegiel J., Gong C.X. Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome. Journal of Alzheimer's Disease 2008, 13:295-302.
96. Liao H., Li Y., Brautigan D.L., Gundersen G.G. Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein tau. Journal of Biological Chemistry 1998, 273:21901-21908.
97. Litersky J.M., Johnson G.V., Jakes R., Goedert M., Lee M., Seubert P. Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochemical Journal 1996, 316(Pt 2):655-660.
98. Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. European Journal of Neuroscience 2005, 22:1942-1950.
99. Liu F., Iqbal K., Grundke-Iqbal I., Rossie S., Gong C.X. Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease. Journal of Biological Chemistry 2005, 280:1790-1796.
100. Liu F., Zaidi T., Iqbal K., Grundke-Iqbal I., Gong C.X. Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5. Neuroscience 2002, 115:829-837.
101. Liu J. FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. Trends in Pharmacological Sciences 1993, 14:182-188.
102. Liu J., Farmer J.D., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66:807-815.
103. Liu Q., Zhao X., Frissora F., Ma Y., Santhanam R., Jarjoura D., Lehman A., Perrotti D., Chen C.S., Dalton J.T., Muthusamy N., Byrd J.C. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008, 111:275-284.
104. Liu R., Zhou X.W., Tanila H., Bjorkdahl C., Wang J.Z., Guan Z.Z., Cao Y., Gustafsson J.A., Winblad B., Pei J.J. Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. Journal of Cellular and Molecular Medicine 2008, 12:241-257.
105. Liu S.J., Zhang J.Y., Li H.L., Fang Z.Y., Wang Q., Deng H.M., Gong C.X., Grundke-Iqbal I., Iqbal K., Wang J.Z. Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. Journal of Biological Chemistry 2004, 279:50078-50088.
106. Longin S., Jordens J., Martens E., Stevens I., Janssens V., Rondelez E., De Baere I., Derua R., Waelkens E., Goris J., Van Hoof C. An inactive protein phosphatase 2A population is associated with methylesterase and can be re-activated by the phosphotyrosyl phosphatase activator. Biochemical Journal 2004, 380:111-119.
107. Longin S., Zwaenepoel K., Louis J.V., Dilworth S., Goris J., Janssens V. Selection of protein phosphatase 2A regulatory subunits is mediated by the C terminus of the catalytic Subunit. Journal of Biological Chemistry 2007, 282:26971-26980.
108. Longin S., Zwaenepoel K., Martens E., Louis J.V., Rondelez E., Goris J., Janssens V. Spatial control of protein phosphatase 2A (de)methylation. Experimental Cell Research 2008, 314:68-81.
109. Lubert E.J., Hong Y., Sarge K.D. Interaction between protein phosphatase 5 and the A subunit of protein phosphatase 2A: evidence for a heterotrimeric form of protein phosphatase 5. Journal of Biological Chemistry 2001, 276:38582-38587.
110. Luo W., Dou F., Rodina A., Chip S., Kim J., Zhao Q., Moulick K., Aguirre J., Wu N., Greengard P., Chiosis G. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:9511-9516.
111. MacKintosh C., Klumpp S. Tautomycin from the bacterium Streptomyces verticillatus, another potent and specific inhibitor of protein phosphatases 1 and 2A. FEBS Letters 1990, 277:137-140.
112. Madeira A., Pommet J.M., Prochiantz A., Allinquant B. SET protein (TAF1beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain. FASEB Journal 2005, 19:1905-1907.
113. Martin L., Latypova X., Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochemistry International 2011, 58:458-471.
114. Martin L., Magnaudeix A., Esclaire F., Yardin C., Terro F. Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A. Brain Research 2009, 1252:66-75.
115. Martin L., Magnaudeix A., Wilson C.M., Yardin C., Terro F. The new indirubin derivative inhibitors of glycogen synthase kinase-3,6-BIDECO and 6-BIMYEO, prevent tau phosphorylation and apoptosis induced by the inhibition of protein phosphatase-2A by okadaic acid in cultured neurons. Journal of Neuroscience Research 2011, 89:1802-1811.
116. Martin L., Page G., Terro F. Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3beta. Neurochemistry International 2011, 59:235-250.
117. Merrill A.H., van Echten G., Wang E., Sandhoff K. Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. Journal of Biological Chemistry 1993, 268:27299-27306.
118. Messner D.J., Romeo C., Boynton A., Rossie S. Inhibition of PP2A, but not PP5, mediates p53 activation by low levels of okadaic acid in rat liver epithelial cells. Journal of Cellular Biochemistry 2006, 99:241-255.
119. Millward T.A., Zolnierowicz S., Hemmings B.A. Regulation of protein kinase cascades by protein phosphatase 2A. Trends in Biochemical Sciences 1999, 24:186-191.
120. Mitsuhashi S., Matsuura N., Ubukata M., Oikawa H., Shima H., Kikuchi K. Tautomycetin is a novel and specific inhibitor of serine/threonine protein phosphatase type 1, PP1. Biochemical and Biophysical Research Communications 2001, 287:328-331.
121. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K., Ihara Y. Proline-directed and non-proline-directed phosphorylation of PHF-tau. Journal of Biological Chemistry 1995, 270:823-829.
122. Morita K., Saitoh M., Tobiume K., Matsuura H., Enomoto S., Nishitoh H., Ichijo H. Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress. EMBO Journal 2001, 20:6028-6036.
123. Nairn A.C., Svenningsson P., Nishi A., Fisone G., Girault J.A., Greengard P. The role of DARPP-32 in the actions of drugs of abuse. Neuropharmacology 2004, 47(Suppl 1):14-23.
124. Nayeem N., Kerr F., Naumann H., Linehan J., Lovestone S., Brandner S. Hyperphosphorylation of tau and neurofilaments and activation of CDK5 and ERK1/2 in PTEN-deficient cerebella. Molecular and Cellular Neurosciences 2007, 34:400-408.
125. Noble W., Pooler A.M., Hanger D.P. Advances in tau-based drug discovery. Expert Opinion on Drug Discovery^pV 6 2011, 797-810.
126. Ogris E., Du X., Nelson K.C., Mak E.K., Yu X.X., Lane W.S., Pallas D.C. A protein phosphatase methylesterase PME-1) is one of several novel proteins stably associating with two inactive mutants of protein phosphatase 2A. Journal of Biological Chemistry 1999, 274:14382-14391.
127. Ouimet C.C., da Cruz e Silva E.F. Greengard P The alpha and gamma 1 isoforms of protein phosphatase 1 are highly and specifically concentrated in dendritic spines. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:3396-3400.
128. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402:615-622.
129. Paudel H.K. The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase. Journal of Biological Chemistry 1997, 272:1777-1785.
130. Pei J.J., Braak H., An W.L., Winblad B., Cowburn R.F., Iqbal K., Grundke-Iqbal I. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Research Molecular Brain Research 2002, 109:45-55.
131. Pei J.J., Gong C.X., An W.L., Winblad B., Cowburn R.F., Grundke-Iqbal I., Iqbal K. Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. American Journal of Pathology 2003, 163:845-858.
132. Pei J.J., Tanaka T., Tung Y.C., Braak E., Iqbal K., Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. Journal of Neuropathology and Experimental Neurology 1997, 56:70-78.
133. Perrotti D., Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer and Metastasis Reviews 2008, 27:159-168.
134. Perry G., Roder H., Nunomura A., Takeda A., Friedlich A.L., Zhu X., Raina A.K., Holbrook N., Siedlak S.L., Harris P.L., Smith M.A. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 1999, 10:2411-2415.
135. Poppek D., Keck S., Ermak G., Jung T., Stolzing A., Ullrich O., Davies K.J., Grune T. Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. Biochemical Journal 2006, 400:511-520.
136. Qian W., Shi J., Yin X., Iqbal K., Grundke-Iqbal I., Gong C.X., Liu F. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. Journal of Alzheimer's Disease 2010, 19:1221-1229.
137. Rahman A., Grundke-Iqbal I., Iqbal K. Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated tau is a preferred substrate of protein phosphatase-1. Neurochemical Research 2005, 30:277-287.
138. Rahman A., Grundke-Iqbal I., Iqbal K. PP2B isolated from human brain preferentially dephosphorylates Ser-262 and Ser-396 of the Alzheimer disease abnormally hyperphosphorylated tau. Journal of Neural Transmission 2006, 113:219-230.
139. Resjo S., Oknianska A., Zolnierowicz S., Manganiello V., Degerman E. Phosphorylation and activation of phosphodiesterase type 3B (PDE3B) in adipocytes in response to serine/threonine phosphatase inhibitors: deactivation of PDE3B in vitro by protein phosphatase type 2A. Biochemical Journal 1999, 341(Pt 3):839-845.
140. Rickle A., Bogdanovic N., Volkmann I., Zhou X., Pei J.J., Winblad B., Cowburn R.F. PTEN levels in Alzheimer's disease medial temporal cortex. Neurochemistry International 2006, 48:114-123.
141. Rusnak F., Mertz P. Calcineurin: form and function. Physiological Reviews 2000, 80:1483-1521.
142. Ruteshouser E.C., Ashworth L.K., Huff V. Absence of PPP2R1A mutations in Wilms tumor. Oncogene 2001, 20:2050-2054.
143. Ruvolo P.P., Clark W., Mumby M., Gao F., May W.S. A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. Journal of Biological Chemistry 2002, 277:22847-22852.
144. Ryoo S.R., Jeong H.K., Radnaabazar C., Yoo J.J., Cho H.J., Lee H.W., Kim I.S., Cheon Y.H., Ahn Y.S., Chung S.H., Song W.J. DYRK1A-mediated hyperphosphorylation of tau. A functional link between Down syndrome and Alzheimer disease. Journal of Biological Chemistry 2007, 282:34850-34857.
145. Saito T., Ishiguro K., Uchida T., Miyamoto E., Kishimoto T., Hisanaga S. In situ dephosphorylation of tau by protein phosphatase 2A and 2B in fetal rat primary cultured neurons. FEBS Letters 1995, 376:238-242.
146. Sanchez-Ortiz E., Hahm B.K., Armstrong D.L., Rossie S. Protein phosphatase 5 protects neurons against amyloid-beta toxicity. Journal of Neurochemistry 2009, 111:391-402.
147. Sato S., Cerny R.L., Buescher J.L., Ikezu T. Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. Journal of Neurochemistry 2006, 98:1573-1584.
148. Schmelzle T., Beck T., Martin D.E., Hall M.N. Activation of the RAS/cyclic AMP pathway suppresses a TOR deficiency in yeast. Molecular and Cellular Biology 2004, 24:338-351.
149. Schmid A.C., Byrne R.D., Vilar R., Woscholski R. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Letters 2004, 566:35-38.
150. Schwab C., DeMaggio A.J., Ghoshal N., Binder L.I., Kuret J., McGeer P.L. Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiology of Aging 2000, 21:503-510.
151. Sengupta A., Wu Q., Grundke-Iqbal I., Iqbal K., Singh T.J. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Molecular and Cellular Biochemistry 1997, 167:99-105.
152. Seubert P., Mawal-Dewan M., Barbour R., Jakes R., Goedert M., Johnson G.V., Litersky J.M., Schenk D., Lieberburg I., Trojanowski J.Q., et al. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. Journal of Biological Chemistry 1995, 270:18917-18922.
153. Shibasaki F., Hallin U., Uchino H. Calcineurin as a multifunctional regulator. Journal of Biochemistry 2002, 131:1-15.
154. Shirazi S.K., Wood J.G. The protein tyrosine kinase, fyn, in Alzheimer's disease pathology. Neuroreport 1993, 4:435-437.
155. Shoji M., Iwakami N., Takeuchi S., Waragai M., Suzuki M., Kanazawa I., Lippa C.F., Ono S., Okazawa H. JNK activation is associated with intracellular beta-amyloid accumulation. Brain Research Molecular Brain Research 2000, 85:221-233.
156. Singh T.J., Wang J.Z., Novak M., Kontzekova E., Grundke-Iqbal I., Iqbal K. Calcium/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules. FEBS Letters 1996, 387:145-148.
157. Skinner J., Sinclair C., Romeo C., Armstrong D., Charbonneau H., Rossie S. Purification of a fatty acid-stimulated protein-serine/threonine phosphatase from bovine brain and its identification as a homolog of protein phosphatase 5. Journal of Biological Chemistry 1997, 272:22464-22471.
158. Smith J.A., Zhang R., Varma A.K., Das A., Ray S.K., Banik N.L. Estrogen partially down-regulates PTEN to prevent apoptosis in VSC4. 1 motoneurons following exposure to IFN-gamma. Brain Research 2009.
159. Sonoda Y., Mukai H., Matsuo K., Takahashi M., Ono Y., Maeda K., Akiyama H., Kawamata T. Accumulation of tumor-suppressor PTEN in Alzheimer neurofibrillary tangles. Neuroscience Letters 2010, 471:20-24.
160. Sontag E., Hladik C., Montgomery L., Luangpirom A., Mudrak I., Ogris E., White C.L. 3rd Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. Journal of Neuropathology and Experimental Neurology 2004, 63:1080-1091.
161. Sontag E., Luangpirom A., Hladik C., Mudrak I., Ogris E., Speciale S., White C.L. 3rd Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. Journal of Neuropathology and Experimental Neurology 2004, 63:287-301.
162. Sontag E., Nunbhakdi-Craig V., Lee G., Brandt R., Kamibayashi C., Kuret J., White C.L. 3rd, Mumby MC, Bloom GS Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. Journal of Biological Chemistry 1999, 274:25490-25498.
163. Sontag E., Nunbhakdi-Craig V., Sontag J.M., Diaz-Arrastia R., Ogris E., Dayal S., Lentz S.R., Arning E., Bottiglieri T. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. Journal of Neuroscience 2007, 27:2751-2759.
164. Sontag J.M., Nunbhakdi-Craig V., Montgomery L., Arning E., Bottiglieri T., Sontag E. Folate deficiency induces in vitro and mouse brain region-specific downregulation of leucine carboxyl methyltransferase-1 and protein phosphatase 2A B(alpha) subunit expression that correlate with enhanced tau phosphorylation. Journal of Neuroscience 2008, 28:11477-11487.
165. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H., Tavtigian S.V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics 1997, 15:356-362.
166. Sun L., Liu S.Y., Zhou X.W., Wang X.C., Liu R., Wang Q., Wang J.Z. Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 2003, 118:1175-1182.
167. Swatton J.E., Sellers L.A., Faull R.L., Holland A., Iritani S., Bahn S. Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. European Journal of Neuroscience 2004, 19:2711-2719.
168. Taniguchi T., Kawamata T., Mukai H., Hasegawa H., Isagawa T., Yasuda M., Hashimoto T., Terashima A., Nakai M., Mori H., Ono Y., Tanaka C. Phosphorylation of tau is regulated by PKN. Journal of Biological Chemistry 2001, 276:10025-10031.
169. Tanimukai H., Grundke-Iqbal I., Iqbal K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. American Journal of Pathology 2005, 166:1761-1771.
170. Tanimukai H., Kudo T., Tanaka T., Grundke-Iqbal I., Iqbal K., Takeda M. Novel therapeutic strategies for neurodegenerative disease. Psychogeriatrics 2009, 9:103-109.
171. Tian Q., Lin Z.Q., Wang X.C., Chen J., Wang Q., Gong C.X., Wang J.Z. Injection of okadaic acid into the meynert nucleus basalis of rat brain induces decreased acetylcholine level and spatial memory deficit. Neuroscience 2004, 126:277-284.
172. Tian Q., Zhang J.X., Zhang Y., Wu F., Tang Q., Wang C., Shi Z.Y., Zhang J.H., Liu S., Wang Y., Zhang Q., Wang J.Z. Biphasic effects of forskolin on tau phosphorylation and spatial memory in rats. Journal of Alzheimer's Disease 2009.
173. Torres J., Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus, implications for PTEN stability to proteasome-mediated degradation. Journal of Biological Chemistry 2001, 276:993-998.
174. Tremblay M.A., Acker C.M., Davies P. Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. Journal of Alzheimer's Disease 2010, 19:721-733.
175. Tsujio I., Zaidi T., Xu J., Kotula L., Grundke-Iqbal I., Iqbal K. Inhibitors of protein phosphatase-2A from human brain structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated tau. FEBS Letters 2005, 579:363-372.
176. Umahara T., Uchihara T., Tsuchiya K., Nakamura A., Iwamoto T., Ikeda K., Takasaki M. (14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease. Acta Neuropathologica 2004, 108:279-286.
177. Vale C., Botana L.M. Marine toxins and the cytoskeleton: okadaic acid and dinophysistoxins. FASEB Journal 2008, 275:6060-6066.
178. Van Hoof C., Goris J. Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question. Biochimica et Biophysica Acta 2003, 1640:97-104.
179. Vazquez F., Ramaswamy S., Nakamura N., Sellers W.R. Phosphorylation of the PTEN tail regulates protein stability and function. Molecular and Cellular Biology 2000, 20:5010-5018.
180. Vega I.E., Cui L., Propst J.A., Hutton M.L., Lee G., Yen S.H. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates. Brain Research Molecular Brain Research 2005, 138:135-144.
181. Vintem A.P., Henriques A.G., da Cruz E.S.O.A., da Cruz E.S.E.F. PP1 inhibition by Abeta peptide as a potential pathological mechanism in Alzheimer's disease. Neurotoxicology and Teratology 2009, 31:85-88.
182. Virshup D.M., Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Molecular Cell 2009, 33:537-545.
183. Vogelsberg-Ragaglia V., Schuck T., Trojanowski J.Q., Lee V.M. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Experimental Neurology 2001, 168:402-412.
184. Walsh A.H., Cheng A., Honkanen R.E. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Letters 1997, 416:230-234.
185. Wang C., Chang K.C., Somers G., Virshup D., Ang B.T., Tang C., Yu F., Wang H. Protein phosphatase 2A regulates self-renewal of Drosophila neural stem cells. Development 2009, 136:2287-2296.
186. Wang J.Z., Gong C.X., Zaidi T., Grundke-Iqbal I., Iqbal K. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. Journal of Biological Chemistry 1995, 270:4854-4860.
187. Wang J.Z., Grundke-Iqbal I., Iqbal K. Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A, -2B and -1. Brain Research Molecular Brain Research 1996, 38:200-208.
188. Wang J.Z., Grundke-Iqbal I., Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. European Journal of Neuroscience 2007, 25:59-68.
189. Wang X., Blanchard J., Kohlbrenner E., Clement N., Linden R.M., Radu A., Grundke-Iqbal I., Iqbal K. The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. FASEB Journal 2010, 24:4420-4432.
190. Wang Z.F., Li H.L., Li X.C., Zhang Q., Tian Q., Wang Q., Xu H., Wang J.Z. Effects of endogenous beta-amyloid overproduction on tau phosphorylation in cell culture. Journal of Neurochemistry 2006, 98:1167-1175.
191. Weng L., Brown J., Eng C. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Human Molecular Genetics 2001, 10:237-242.
192. Westermarck J., Hahn W.C. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends in Molecular Medicine 2008, 14:152-160.
193. Woods Y.L., Cohen P., Becker W., Jakes R., Goedert M., Wang X., Proud C.G. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochemical Journal 2001, 355:609-615.
194. Xu Y., Chen Y., Zhang P., Jeffrey P.D., Shi Y. Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated Tau dephosphorylation. Molecular Cell 2008, 31:873-885.
195. Xu Y., Xing Y., Chen Y., Chao Y., Lin Z., Fan E., Yu J.W., Strack S., Jeffrey P.D., Shi Y. Structure of the protein phosphatase 2A holoenzyme. Cell 2006, 127:1239-1251.
196. Yamaguchi H., Ishiguro K., Uchida T., Takashima A., Lemere C.A., Imahori K. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathologica 1996, 92:232-241.
197. Yamamoto H., Hiragami Y., Murayama M., Ishizuka K., Kawahara M., Takashima A. Phosphorylation of tau at serine 416 by Ca2+/calmodulin-dependent protein kinase II in neuronal soma in brain. Journal of Neurochemistry 2005, 94:1438-1447.
198. Yan L., Mieulet V., Burgess D., Findlay G.M., Sully K., Procter J., Goris J., Janssens V., Morrice N.A., Lamb R.F. PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR. Molecular Cell 2010, 37:633-642.
199. Yao X.Q., Zhang X.X., Yin Y.Y., Liu B., Luo D.J., Liu D., Chen N.N., Ni Z.F., Wang X., Wang Q., Wang J.Z., Liu G.P. Glycogen synthase kinase-3beta regulates Tyr307 phosphorylation of protein phosphatase-2A via protein tyrosine phosphatase 1B but not Src. Biochemical Journal 2011, 437:335-344.
200. Yasojima K., Kuret J., DeMaggio A.J., McGeer E., McGeer P.L. Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain. Brain Research 2000, 865:116-120.
201. Yin G., Li L.Y., Qu M., Luo H.B., Wang J.Z., Zhou X.W. Upregulation of AKT Attenuates amyloid-beta-induced cell apoptosis. Journal of Alzheimer's Disease 2011.
202. Yin Y.Y., Liu H., Cong X.B., Liu Z., Wang Q., Wang J.Z., Zhu L.Q. Acetyl-l-carnitine attenuates okadaic acid induced tau hyperphosphorylation and spatial memory impairment in rats. Journal of Alzheimer's Disease 2010, 19:735-746.
203. Yoon S.Y., Choi J.E., Kweon H.S., Choe H., Kim S.W., Hwang O., Lee H., Lee J.Y., Kim D.H. Okadaic acid increases autophagosomes in rat neurons: implications for Alzheimer's disease. Journal of Neuroscience Research 2008, 86:3230-3239.
204. Yoshimura Y., Ichinose T., Yamauchi T. Phosphorylation of tau protein to sites found in Alzheimer's disease brain is catalyzed by Ca2+/calmodulin-dependent protein kinase II as demonstrated tandem mass spectrometry. Neuroscience Letters 2003, 353:185-188.
205. Yu X.X., Du X., Moreno C.S., Green R.E., Ogris E., Feng Q., Chou L., McQuoid M.J., Pallas D.C. Methylation of the protein phosphatase 2A catalytic subunit is essential for association of Balpha regulatory subunit but not SG2NA, striatin, or polyomavirus middle tumor antigen. Molecular Biology of the Cell 2001, 12:185-199.
206. Zgheib C., Zouein F.A., Chidiac R., Kurdi M., Booz G.W. Calyculin A reveals serine/threonine phosphatase protein phosphatase 1 as a regulatory nodal point in canonical signal transducer and activator of transcription 3 signaling of human microvascular endothelial cells. Journal of Interferon and Cytokine Research 2012.
207. Zhang C.E., Tian Q., Wei W., Peng J.H., Liu G.P., Zhou X.W., Wang Q., Wang D.W., Wang J.Z. Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiology of Aging 2008, 29:1654-1665.
208. Zhang X., Li F., Bulloj A., Zhang Y.W., Tong G., Zhang Z., Liao F.F., Xu H. Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules. FASEB Journal 2006, 20:1272-1274.
209. Zhou G., Golden T., Aragon I.V., Honkanen R.E. Ser/Thr protein phosphatase 5 inactivates hypoxia-induced activation of an apoptosis signal-regulating kinase 1/MKK-4/JNK signaling cascade. Journal of Biological Chemistry 2004, 279:46595-46605.
210. Zhou X.W., Gustafsson J.A., Tanila H., Bjorkdahl C., Liu R., Winblad B., Pei J.J. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiology of Disease 2008, 31:386-394.
211. Zhou X.W., Winblad B., Guan Z., Pei J.J. Interactions between glycogen synthase kinase 3beta, protein kinase B, and protein phosphatase 2A in tau phosphorylation in mouse N2a neuroblastoma cells. Journal of Alzheimer's Disease 2009.
212. Zhu L.Q., Zheng H.Y., Peng C.X., Liu D., Li H.L., Wang Q., Wang J.Z. Protein phosphatase 2A facilitates axonogenesis by dephosphorylating CRMP2. Journal of Neuroscience 2010, 30:3839-3848.
213. Zhu X., Raina A.K., Rottkamp C.A., Aliev G., Perry G., Boux H., Smith M.A. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. Journal of Neurochemistry 2001, 76:435-441.
214. Zhu X., Rottkamp C.A., Boux H., Takeda A., Perry G., Smith M.A. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. Journal of Neuropathology and Experimental Neurology 2000, 59:880-888.